Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
Date:2/17/2011

uvan, Firdapse, and its product candidates; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme, Kuvan, and Firdapse; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials, particularly with respect to GALNS, Firdapse, PEG-PAL, BMN 673 and BMN 701; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products and particularly Aldurazyme, Naglazyme, Kuvan and Firdapse; actual sales of Aldurazyme, Naglazyme Kuvan and Firdapse; Merck Serono's activities related to Kuvan; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2009 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC. BIOMARIN PHARMACEUTICAL INC. CONSOLIDATED BALANCE
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
2. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
3. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
4. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
5. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
6. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
7. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
8. BioMarin Announces Third Quarter 2010 Financial Results
9. BioMarin to Host a Research and Development Day on October 19th
10. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
11. BioMarin to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  Seres Health, a clinical-stage therapeutics company ... human microbiome, announced today that Dr. David ... and Chief Scientific Officer, will be presenting at ... Chemotherapy (ICAAC). The presentation will highlight the scientific ... of bacterial spores derived from the human microbiome, ...
(Date:8/28/2014)... 2014   Venaxis, Inc.  (Nasdaq:  APPY), an ... clearance for and commercializing its CE Marked APPY ... identifying children, adolescent, and young adult patients in the ... today announced it will present at three upcoming investor ... Global Investment Conference being held in New ...
(Date:8/28/2014)... PLYMOUTH MEETING, Pa. , Aug. 28, 2014 ... surgical community, patients, and media, both for the ... to patient safety. The quick deployment of surgical ... new technology are prompting facilities to evaluate their ... for the entire surgical team.    ...
Breaking Medicine Technology:Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5
... Delcath Systems, Inc. (Nasdaq: DCTH ) today ... of Directors. Dr. Contag is a proven corporate executive with ... , (LOGO: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ... Cobalt Technologies, Inc. in 2006 and served as CEO. Prior ...
... & Alzheimer,s Disease , , ... today announced that its researchers have uncovered a new ... a potential target for developing novel therapeutics for intervention ... Institute,s Pancham Bakshi, Ph.D., is detailed in the ...
Cached Medicine Technology:Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 3Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease 2Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease 3
(Date:8/28/2014)... 28, 2014 Testimony began this ... a transvaginal mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ )involving ... LLP reports. Court documents pending in the U.S. ... that the case was filed on behalf of ... surgeries, allegedly due to vaginal mesh complications associated ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 The Governor ... Microcredit Summit at a press conference; this event ... with the Ministry of Economy through the National Microenterprise ... from September 2nd to the 5th at the Convention ... , “It is a great responsibility for Yucatan to ...
(Date:8/28/2014)... Kirklyn Smith, an office manager for EzCOI.com , is ... by walking 5,000 miles in a single year without ever ... thousands of individual stories of TrekDesk treadmill desk users across ... than the others. , Kirklyn has launched a website that ... range of 54,823 steps (presumably on an off day) to ...
(Date:8/28/2014)... August 28, 2014 Bank lending to the ... year, down by 0.13% in real terms, and continuing to ... new study by UHY, the international accountancy network. , UHY ... businesses in particular, the credit crunch lingers on. , UHY ... the last year have been wiped out by inflation. Over ...
(Date:8/28/2014)... of sleep not only puts teens at risk for poor ... researchers warn. The study authors analyzed data collected from ... 21. Nearly one-fifth of them got less than six hours ... this group was 20 percent more likely to be obese ... hours of sleep per night at age 16, the investigators ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Less Sleep in Teen Years Tied to More Pounds at 21 2
... new study, a serious form of cancer that arises in ... normally serve as ‘scouts’ for the immune system. ... virus (EBV), which is usually kept under check by the ... control is lost and the transplanted organ may be rejected. ...
... characterized by pain and tenderness in the jaw muscles ... ,TMD is a problem for millions of Americans whose ... open-joint surgery. Whole system naturopathic care as a treatment ... of a new study involving 160 women in the ...
... a research conducted to study the link between work-related ... real or threatened violence at workplace run a major ... showed that the magnitude of the risk was in ... ,The findings of the study have been published ...
... of just a few puffs of cigarette that is capable ... that the amount of nicotine present in a single puff ... receptors and 3 puffs can occupy nearly 70% of these ... the receptors are filled up. But this feeling of satisfaction ...
... has now risen to 19 from 17. The official ... encephalitis was spreading rapidly.// ,Health officials in ... infections had emerged since July 13. Encephalitis causes the ... left untreated can be fatal. In China, health authorities ...
... The calories that contribute to ill health are loaded in ... consequentially off the lives of many // , who are ... with, the ideal thing would be to ensure the promotional ... that people are dished out the right information about healthy ...
Cached Medicine News:Health News:Deficient 'Scout Cells' Causes Cancer in Transplant Patients 2Health News:Deficient 'Scout Cells' Causes Cancer in Transplant Patients 3Health News:Naturopathic Care Proves Beneficial for TMD Pain 2Health News:Work-Related Violence Increases Risk Of Depression 2Health News:Imaging study affords renewed thrust on smoking cessation treatments 2Health News:Imaging study affords renewed thrust on smoking cessation treatments 3
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
... Control is designed to ... significant range of those ... during fertility or pregnancy ... hCG-Beta Subunit levels allow ...
... provides the clinical laboratory with the ... for monitoring immunoassay and therapeutic drug ... separate controls. Made from human serum ... suitable for most methods and is ...
Lyphochek Immunology Plus Control is an assayed control for monitoring chemistry procedures that test for autoimmune, anemic, malignant, hepatic and nephrotic-disease states. Available in two levels....
Medicine Products: